Melanoma associated with tumour necrosis factor-α inhibitors: A Research on Adverse Drug events and Reports (RADAR) project

British Journal of Dermatology

Volumn 170, Issue 5, 2014, Pages 1170-1172

  Nardone, B ^a   Hammel, J A ^a   Raisch, D W ^b   Weaver, L L ^a   Schneider, D ^c   West, D P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; RISK FACTOR; SIGNAL DETECTION; SKIN CARCINOGENESIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; SKIN TUMOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; MELANOMA; RISK FACTORS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901044241     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12779     Document Type: Article

References (4)

1. Long MD, Martin CF, Pipkin CA, et al,. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-9.e1.
2. Raaschou P, Simard JF, Holmqvist M, Askling J,. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013; 346: f1939.
3. McKoy JM, Fisher MJ, Courtney DM, et al,. Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 2013; 36: 335-47.
4. Sakaeda T, Tamon A, Kadoyama K, Okuno Y,. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 2013; 10: 796-803.